A Y Shah1, R R Kotecha2, E A Lemke3, A Chandramohan4, J L Chaim5, P Msaouel3, L Xiao6, J Gao3, M T Campbell3, A J Zurita3, J Wang3, P G Corn3, E Jonasch3, R J Motzer7, P Sharma3, M H Voss7, N M Tannir3. 1. Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ayshah@mdanderson.org. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA. 7. Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) are being increasingly utilised in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited data exist on responses and survival on second-line (2L) vascular endothelial growth factor-receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy after 1L ICI therapy. PATIENTS AND METHODS: This is a retrospective study of mccRCC patients treated with 2L VEGFR-TKI after progressive disease (PD) with 1L ICI. Patients were treated at MD Anderson Cancer Center or Memorial Sloan Kettering Cancer Center between December 2015 and February 2018. Objective response was assessed by blinded radiologists' review using Response Evaluation Criteria in Solid Tumours v1.1. Descriptive statistics and Kaplan-Meier method were used. RESULTS: Seventy patients were included in the analysis. Median age at mccRCC diagnosis was 59 years; 8 patients (11%) had international metastatic database consortium favourable-risk disease, 48 (69%) had intermediate-risk disease and 14 (20%) had poor-risk disease. As 1L therapy, 12 patients (17%) received anti-programmed death ligand-1 (PD-(L)1) monotherapy with nivolumab or atezolizumab, 33 (47%) received nivolumab plus ipilimumab and 25 (36%) received combination anti-PD-(L)1 plus bevacizumab. 2L TKI therapies included pazopanib, sunitinib, axitinib and cabozantinib. On 2L TKI therapy, one patient (1.5%) achieved a complete response, 27 patients (39.7%) a partial response and 36 patients (52.9%) stable disease. Median progression-free survival (mPFS) was 13.2 months (95% confidence interval: 10.1, NA). Forty-five percent of subjects required a dose reduction, and twenty-seven percent of patients discontinued treatment because of toxicity. CONCLUSIONS: In this retrospective study of patients with mccRCC receiving 2L TKI monotherapy after 1L ICI, we observed 2L antitumour activity and tolerance comparable to historical data for 1L TKI.
BACKGROUND: Immune checkpoint inhibitors (ICIs) are being increasingly utilised in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited data exist on responses and survival on second-line (2L) vascular endothelial growth factor-receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy after 1L ICI therapy. PATIENTS AND METHODS: This is a retrospective study of mccRCC patients treated with 2L VEGFR-TKI after progressive disease (PD) with 1L ICI. Patients were treated at MD Anderson Cancer Center or Memorial Sloan Kettering Cancer Center between December 2015 and February 2018. Objective response was assessed by blinded radiologists' review using Response Evaluation Criteria in Solid Tumours v1.1. Descriptive statistics and Kaplan-Meier method were used. RESULTS: Seventy patients were included in the analysis. Median age at mccRCC diagnosis was 59 years; 8 patients (11%) had international metastatic database consortium favourable-risk disease, 48 (69%) had intermediate-risk disease and 14 (20%) had poor-risk disease. As 1L therapy, 12 patients (17%) received anti-programmed death ligand-1 (PD-(L)1) monotherapy with nivolumab or atezolizumab, 33 (47%) received nivolumab plus ipilimumab and 25 (36%) received combination anti-PD-(L)1 plus bevacizumab. 2L TKI therapies included pazopanib, sunitinib, axitinib and cabozantinib. On 2L TKI therapy, one patient (1.5%) achieved a complete response, 27 patients (39.7%) a partial response and 36 patients (52.9%) stable disease. Median progression-free survival (mPFS) was 13.2 months (95% confidence interval: 10.1, NA). Forty-five percent of subjects required a dose reduction, and twenty-seven percent of patients discontinued treatment because of toxicity. CONCLUSIONS: In this retrospective study of patients with mccRCC receiving 2L TKI monotherapy after 1L ICI, we observed 2L antitumour activity and tolerance comparable to historical data for 1L TKI.
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Nizar M Tannir; Paul N Mainwaring; Brian I Rini; Hans J Hammers; Frede Donskov; Bruce J Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y C Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N Sternberg; David F McDermott; Dana T Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E Hutson; Sumanta Pal; Robert J Motzer Journal: Lancet Oncol Date: 2016-06-05 Impact factor: 41.316
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer Journal: Lancet Date: 2011-11-04 Impact factor: 79.321
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Laurence Albiges; André P Fay; Wanling Xie; Katherine Krajewski; David F McDermott; Daniel Y C Heng; Charles Dariane; Guillermo DeVelasco; Renee Lester; Bernard Escudier; Toni K Choueiri Journal: Eur J Cancer Date: 2015-09-04 Impact factor: 9.162
Authors: Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri Journal: N Engl J Med Date: 2019-02-16 Impact factor: 91.245
Authors: Thomas Powles; Robert J Motzer; Bernard Escudier; Sumanta Pal; Christian Kollmannsberger; Joanna Pikiel; Howard Gurney; Sun Young Rha; Se Hoon Park; Poul F Geertsen; Marine Gross-Goupil; Enrique Grande; Cristina Suarez; David W Markby; Alan Arroyo; Mark Dean; Toni K Choueiri; Daniel George Journal: Br J Cancer Date: 2018-09-10 Impact factor: 7.640
Authors: Samantha Armstrong; Tina Roy; Bhavana Singh; Monika Kulasekaran; Fatima Shaukat; Xue Geng; Hongkun Wang; Petra Prins; Reena C Jha; Marion L Hartley; Aiwu Ruth He Journal: J Cancer Res Clin Oncol Date: 2022-06-30 Impact factor: 4.553
Authors: Jacob J Adashek; Joshua J Breunig; Edwin Posadas; Neil A Bhowmick; Leigh Ellis; Stephen J Freedland; Hyung Kim; Robert Figlin; Jun Gong Journal: Drugs Date: 2022-02-17 Impact factor: 9.546
Authors: Leo L Tsai; Rupal S Bhatt; Meaghan F Strob; Opeyemi A Jegede; Maryellen R M Sun; David C Alsop; Paul Catalano; David McDermott; Philip M Robson; Michael B Atkins; Ivan Pedrosa Journal: Radiology Date: 2020-12-01 Impact factor: 11.105